Hypertension in neonates treated with intravitreal bevacizumab for retinopathy of prematurity.
J Perinatol
; 41(6): 1426-1431, 2021 06.
Article
en En
| MEDLINE
| ID: mdl-33686120
ABSTRACT
OBJECTIVE:
To investigate if preterm neonates developed systemic hypertension after intravitreal bevacizumab for retinopathy of prematurity.METHODS:
Patients who received treatment between January 1, 2011 and January 31, 2019 were eligible for inclusion. Patients with pre-existing hypertension, congenital eye disease, or who were discharged within 72 h of treatment were excluded. Charts were reviewed for baseline data, co-morbidities, and the development of systemic hypertension within 4 weeks post treatment.RESULTS:
After exclusions, 64 patients were analyzed. New-onset systemic hypertension was identified in 44 (69%) infants. There were no statistical differences in the demographic characteristics or presence of co-morbidities between the hypertensive and non-hypertensive groups. Of those who developed hypertension, the majority presented within the first week post treatment (55%).CONCLUSIONS:
The majority of infants who received intravitreal bevacizumab developed new-onset systemic hypertension after treatment. Further studies may explore hypertension as a potential side effect of bevacizumab in the neonatal population.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Retinopatía de la Prematuridad
/
Hipertensión
Tipo de estudio:
Prognostic_studies
Límite:
Humans
/
Newborn
Idioma:
En
Revista:
J Perinatol
Asunto de la revista:
PERINATOLOGIA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos